Emerging Spinecare Trends
Redefining and Restaging Disease
Advances in spine research and molecular imaging will
redefine early stage spine disease. In vivo molecular imaging will also
change the way we stage spine disease including spinal tumors. Emphasis
will shift from anatomical (structural) imaging to integrated anatomical
and in vivo biochemical imaging. Biochemical evidence of spine disease
will likely precede structural pathology and classic signs and symptoms.
Molecular imaging will be used to identify the molecular (biochemical)
borders of tumors/lesions in contrast to focusing on structural
boundaries of pathology. In most cases the biochemical borders of a
lesion will extend beyond the more obvious structural borders seen on
routine imaging studies. The future will bring about a more aggressive
search for chemical and genetic biomarkers of disease. This will include
biomarkers acquired through lab work, imaging and biopsies. Disease
biomarkers will be correlated to help stratify the stages of spine
disease.